Conversion of CTLA-4 from Inhibitor to Activator of T Cells with a Bispecific Tandem Single-Chain Fv Ligand1

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Immunology

• Publication date

  2004-05-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4049/jimmunol.172.10.5948PMID 15128776
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Engineered antibodies

  2003cited by this paper
• Viewpoint: Therapeutic Implications of CTLA‐4 Compartmentalization

  2003cited by this paper
• Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling

  2003cited by this paper
• Bispecific antibodies for polyclonal T-cell engagement.

  2003cited by this paper
• Short cytoplasmic SDYMNM segment of CD28 is sufficient to convert CTLA‐4 to a positive signaling receptor

  2003cited by this paper
• Topological Requirements and Signaling Properties of T Cell–activating, Anti-CD28 Antibody Superagonists

  2003cited by this paper
• Antibody engineering for therapeutics.

  2003cited by this paper
• Positive and negative regulation of T-cell activation through kinases and phosphatases.

  2003cited by this paper
• A recombinant bispecific single‐chain antibody induces targeted, supra‐agonistic CD28‐stimulation and tumor cell killing

  2003cited by this paper
• Biochemical and pharmacological control of the multiplicity of coupling at G-protein-coupled receptors.

  2003cited by this paper
• Crystal structure of the receptor-binding domain of human B7-2: Insights into organization and signaling

  2003cited by this paper
• CD28, Costimulator or Agonist Receptor?

  2003cited by this paper
• Assembly of Cell Regulatory Systems Through Protein Interaction Domains

  2003cited by this paper
• Negative feedback of T cell activation through inhibitory adapters and costimulatory receptors

  2003cited by this paper
• Negative Regulation of T Cell Receptor–Lipid Raft Interaction by Cytotoxic T Lymphocyte–associated Antigen 4

  2003cited by this paper
• Surface Cytotoxic T Lymphocyte–associated Antigen 4 Partitions Within Lipid Rafts and Relocates to the Immunological Synapse under Conditions of Inhibition of T Cell Activation

  2002cited by this paper
• Inhibition of CTLA-4 Function by the Regulatory Subunit of Serine/Threonine Phosphatase 2A1

  2002cited by this paper
• Structural mechanisms of costimulation

  2002cited by this paper
• Okadaic acid: the archetypal serine/threonine protein phosphatase inhibitor.

  2002cited by this paper
• CTLA-4: new insights into its biological function and use in tumor immunotherapy

  2002cited by this paper
• Inhibition of Src by direct interaction with protein phosphatase 2A

  2001cited by this paper
• Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation.

  2001cited by this paper
• Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine

  2001cited by this paper
• T-cell regulation by CD28 and CTLA-4

  2001cited by this paper
• Protein phosphatase 2A: the Trojan Horse of cellular signaling.

  2001cited by this paper
• CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy.

  2001cited by this paper
• Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling.

  2001cited by this paper
• Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses

  2001cited by this paper
• Structural basis for co-stimulation by the human CTLA-4/B7-2 complex

  2001cited by this paper
• Phosphorylation of T cell receptor ζ is regulated by a lipid dependent folding transition

  2000cited by this paper
• The CD28 and CTLA-4 receptors associate with the serine/threonine phosphatase PP2A.

  2000cited by this paper
• Induction of CTL Responses by Simultaneous Administration of Liposomal Peptide Vaccine with Anti-CD40 and Anti-CTLA-4 mAb1

  2000cited by this paper
• Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade.

  2000cited by this paper
• Cholesterol depletion disrupts lipid rafts and modulates the activity of multiple signaling pathways in T lymphocytes

  2000cited by this paper
• Blockade of T Cell Activation Using a Surface-Linked Single-Chain Antibody to CTLA-4 (CD152)1

  2000influential reference
• CTLA-4 (CD152) Can Inhibit T Cell Activation by Two Different Mechanisms Depending on Its Level of Cell Surface Expression1

  2000cited by this paper
• Cutting Edge: Tyrosine-Independent Transmission of Inhibitory Signals by CTLA-41

  2000cited by this paper
• The Inhibitory Function of CTLA-4 Does Not Require Its Tyrosine Phosphorylation1

  2000cited by this paper
• Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb

  2000cited by this paper
• Cytotoxic T Lymphocyte Antigen 4 (Ctla-4) Engagement Delivers an Inhibitory Signal through the Membrane-Proximal Region in the Absence of the Tyrosine Motif in the Cytoplasmic Tail

  1999cited by this paper
• Association between src-kinases and the polyoma virus oncogene middle T-antigen requires PP2A and a specific sequence motif

  1999cited by this paper
• G-protein-coupled receptor heterodimerization modulates receptor function

  1999cited by this paper
• Aggregation of Lipid Rafts Accompanies Signaling via the T Cell Antigen Receptor

  1999cited by this paper
• Molecular basis of T cell inactivation by CTLA-4.

  1998cited by this paper
• Nucleic acid vaccine-induced immune responses require CD28 costimulation and are regulated by CTLA4.

  1998cited by this paper
• Mitogenic properties of a bispecific single-chain Fv-Ig fusion generated from CD2-specific mAb to distinct epitopes.

  1998cited by this paper
• CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.

  1998cited by this paper
• Cyclosporin A-resistant transactivation of the IL-2 promoter requires activity of okadaic acid-sensitive serine/threonine phosphatases.

  1998cited by this paper
• Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction

  1998cited by this paper
• B7-CTLA4 interaction enhances both production of antitumor cytotoxic T lymphocytes and resistance to tumor challenge.

  1998cited by this paper
• Dissociation of Intracellular Signaling Pathways in Response to Partial Agonist Ligands of the T Cell Receptor

  1998cited by this paper
• Tyrosine phosphorylation controls internalization of CTLA-4 by regulating its interaction with clathrin-associated adaptor complex AP-2.

  1997cited by this paper
• Interaction of CTLA-4 with AP50, a clathrin-coated pit adaptor protein.

  1997cited by this paper
• CTLA-4–B7 Interaction Is Sufficient to Costimulate T Cell Clonal Expansion

  1997cited by this paper
• Inactivation of lck and loss of TCR-mediated signaling upon persistent engagement with complexes of peptide:MHC molecules.

  1997cited by this paper
• Induction of interleukin‐2 transcription by the hamster polyomavirus middle T antigen: a role for Fyn in T cell signal transduction

  1995cited by this paper
• The two-state model of receptor activation.

  1995cited by this paper
• Tyrosine phosphorylation of protein phosphatase 2A in response to growth stimulation and v-src transformation of fibroblasts.

  1994cited by this paper
• Autophosphorylation‐activated protein kinase inactivates the protein tyrosine phosphatase activity of protein phosphatase 2A

  1994cited by this paper
• Cell calcium signaling via GM1 cell surface gangliosides in the human Jurkat T cell line.

  1994cited by this paper
• "Diabodies": small bivalent and bispecific antibody fragments.

  1993cited by this paper
• Inhibition of the serine/threonine protein phosphatases PP1 and PP2A in lymphocytes: effect on mRNA levels for interleukin-2, IL-2R alpha, krox-24, p53, hsc70 and cyclophilin.

  1992cited by this paper
• Surface expression of alternative forms of the TCR/CD3 complex.

  1991cited by this paper
• Polyoma small and middle T antigens and SV40 small t antigen form stable complexes with protein phosphatase 2A.

  1990cited by this paper
• Requirement for the coexpression of T3 and the T cell antigen receptor on a malignant human T cell line

  1984cited by this paper

• Protein Phosphatase 2A Promotes CD8+ T Cell Effector Function through the Augmentation of CD28 Costimulation

  2024cites this paper
• Biology drives the discovery of bispecific antibodies as innovative therapeutics.

  2020cites this paper
• Immune Checkpoint Inhibitors: A Step forward in Cancer Management

  2019cites this paper
• Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells

  2019cites this paper
• Current progress in innovative engineered antibodies

  2017cites this paper
• CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells.

  2014cites this paper
• 11. Bispecific Antibodies

  2014cites this paper
• A bispecific antibody against two different epitopes on hepatitis B surface antigen has potent hepatitis B virus neutralizing activity

  2013cites this paper
• Histoon H3 metülatsiooni mustrid CTLA4ekspressiooni regulatsioonis erinevates T-rakkude alapopulatsioonides

  2013cites this paper
• Basic Science for the Clinician 55: CTLA-4

  2012cites this paper
• Natural Killer (NK)- and T-Cell Engaging Antibody-Derived Therapeutics

  2012cites this paper
• Anticalins in Drug Development

  2012cites this paper
• T Cell Activation and Function: Role of Signal Strength

  2011cites this paper
• Bispecific Antibodies: Developments and Current Perspectives

  2011cites this paper
• Identification of cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) isoforms in the Pekin duck.

  2010cites this paper
• Rationale and development of multispecific antibody drugs

  2010cites this paper
• Structure-Function analysis of the CTLA-4 interaction with PP2A

  2009cites this paper
• Association of CTLA-4 polymorphisms and clinical-immunologic characteristics at onset of type 1 diabetes mellitus in children.

  2009cites this paper
• Intracellular concentrations of Ca2+ modulate the strength of signal and alter the outcomes of cytotoxic T‐lymphocyte antigen‐4 (CD152)–CD80/CD86 interactions in CD4+ T lymphocytes

  2009cites this paper
• Immune intervention with monoclonal antibodies targeting CD152 (CTLA-4) for autoimmune and malignant diseases.

  2008influential citation
• Considerations for the development of therapeutic monoclonal antibodies.

  2008cites this paper
• Characterization of oligomers induced by inverse agonists of CTLA-4.

  2008cites this paper
• Site-directed in vitro immunization leads to a complete human monoclonal IgG4λ that binds specifically to the CDR2 region of CTLA-4 (CD152) without interfering the engagement of natural ligands

  2007cites this paper
• Mitogenic CD 28 Signals Require the Exchange Factor Vav 1 to Enhance TCR Signaling at the SLP-76-Vav-Itk Signalosome 1

  2007cites this paper
• Pivotal Advance: CTLA‐4+ T cells exhibit normal antiviral functions during acute viral infection

  2007cites this paper
• Mitogenic CD28 Signals Require the Exchange Factor Vav1 to Enhance TCR Signaling at the SLP-76-Vav-Itk Signalosome1

  2007cites this paper
• Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin

  2007cites this paper
• Molecular Determinants of Inverse Agonist Activity of Biologicals Targeting CTLA-41

  2007cites this paper
• Activity of Biologicals Targeting CTLA-4 Molecular Determinants of Inverse Agonist

  2007cites this paper
• The immunological synapse as a novel therapeutic target.

  2006cites this paper
• A molecular perspective of CTLA-4 function.

  2006cites this paper
• CTLA‐4 lacking the cytoplasmic domain costimulates IL‐2 production in T‐cell hybridomas

  2006cites this paper
• Modulation of cell cycle progression by CTLA4‐CD80/CD86 interactions on CD4+ T cells depends on strength of the CD3 signal: critical role for IL‐2

  2006cites this paper
• The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation.

  2005cites this paper
• Lipocalins in drug discovery: from natural ligand-binding proteins to "anticalins".

  2005cites this paper
• CTLA4‐CD80/CD86 interactions on primary mouse CD4+ T cells integrate signal‐strength information to modulate activation with Concanavalin A

  2005cites this paper
• T cell costimulation in anti-tumor immunity and autoimmunity.

  2004cites this paper